BioStock: ExpreS2ion´s CEO on current development and the rights issue

ExpreS2ion Biotechnologies is eagerly awaiting top-line results from the phase III study with its Covid-19 vaccine. Meanwhile the cancer vaccine candidate ES2B-C001 is advancing towards the clinic. BioStock spoke to CEO Bent U. Frandsen to find out more about the development plans and the unit issue that will pave the way for further development.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/03/expres2ions-ceo-on-current-development-and-the-rights-issue/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se